PTK2 and hepatocellular carcinoma: For example, sorafenib resistance in hepatocellular carcinoma is caused by protein tyrosine kinase 2 (PTK2) promoter hypomethylation, which also causes PTK2 overexpression and stimulates the signaling pathway of Wnt.49